Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma multiforme |
| ICD-0-3 | NA |
| Methods | qPCR, RNAi, Western blot, Luciferase reporter assay etc. |
| Sample | GBM tissues, serum, cell lines (U87 and U251) |
| Expression Pattern | down-regulated |
| Function Description | Four lncRNAs (MALAT1, LOC100506474, MEG3 and PRNCR1) were found significantly dysregulated in responding tissues compared with non-responding tissues. Only MALAT1 was significantly desregulated in serum. LncRNA MALAT1 inhibition re-sensitized TMZ resistant cells through up-regulating miR-203 and down-regulating TS expression. On the other hand, MALAT1 overexpression promoted resistance by suppressing miR-203 and promoting TS expression. |
| Pubmed ID | 28187000 |
| Year | 2017 |
| Title | MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for glioblastoma multiforme | OMIM COSMIC |